TW201612314A - Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases - Google Patents

Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases

Info

Publication number
TW201612314A
TW201612314A TW104119530A TW104119530A TW201612314A TW 201612314 A TW201612314 A TW 201612314A TW 104119530 A TW104119530 A TW 104119530A TW 104119530 A TW104119530 A TW 104119530A TW 201612314 A TW201612314 A TW 201612314A
Authority
TW
Taiwan
Prior art keywords
diseases
stem cells
ligustilide
treating autoimmune
efficacy
Prior art date
Application number
TW104119530A
Other languages
Chinese (zh)
Other versions
TWI625392B (en
Inventor
Shinn-Zong Lin
Horng-Jyh Harn
Shih-Ping Liu
Ru-Huei Fu
Po-Cheng Lin
Ming-Hsi Chuang
Original Assignee
Gwo Xi Stem Cell Applied Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwo Xi Stem Cell Applied Technology Co Ltd filed Critical Gwo Xi Stem Cell Applied Technology Co Ltd
Priority to TW104119530A priority Critical patent/TWI625392B/en
Publication of TW201612314A publication Critical patent/TW201612314A/en
Application granted granted Critical
Publication of TWI625392B publication Critical patent/TWI625392B/en

Links

Abstract

A use of ligustilide is provided, including the use of ligustilide to enhance the therapeutic effect of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases, as well as the use of a combination of ligustilide and ligustilide-treated stem cells on the aforementioned stem cell therapy. With the treatment of ligustilide, stem cells can provide an enhanced therapeutic effect. Such treatment especially can increase the expression of differentiation-promoting genes in stem cells, increase the expression of homing-promoting genes in stem cells, and/or decrease the expression of inflammatory genes in stem cells.
TW104119530A 2014-09-17 2014-09-17 Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases TWI625392B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW104119530A TWI625392B (en) 2014-09-17 2014-09-17 Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW104119530A TWI625392B (en) 2014-09-17 2014-09-17 Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases

Publications (2)

Publication Number Publication Date
TW201612314A true TW201612314A (en) 2016-04-01
TWI625392B TWI625392B (en) 2018-06-01

Family

ID=56360767

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104119530A TWI625392B (en) 2014-09-17 2014-09-17 Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases

Country Status (1)

Country Link
TW (1) TWI625392B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781322B (en) * 2019-05-27 2022-10-21 台灣粒線體應用技術股份有限公司 A culture composition and an use for improving the function of mitochondria thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397272B (en) * 2010-09-17 2013-08-14 石药集团恩必普药业有限公司 Application of butylphthalide and derivatives thereof in preparation of medicines for preventing and treating ALS
TWI487521B (en) * 2013-03-12 2015-06-11 Hawking Biolog Technology Co Ltd Use of phthalide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781322B (en) * 2019-05-27 2022-10-21 台灣粒線體應用技術股份有限公司 A culture composition and an use for improving the function of mitochondria thereof

Also Published As

Publication number Publication date
TWI625392B (en) 2018-06-01

Similar Documents

Publication Publication Date Title
EA201790737A1 (en) COMBINED THERAPY
PH12016500841A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
MY186702A (en) Compositions and methods of use for treating metabolic disorders
CA160630S (en) Body groomer
MX2015007751A (en) Anti-gdf15 antibodies.
MX2017011834A (en) Peptidomimetic macrocycles and uses thereof.
CL2015002807A1 (en) Combination therapy
PE20150223A1 (en) ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM
IN2015DN00895A (en)
MX2017003797A (en) Peptidomimetic macrocycles and uses thereof.
NZ602798A (en) Treatment of sarcoidosis using placental stem cells
MX2015012922A (en) Cancer treatment using antibodies that bing cell surface grp78.
MY185016A (en) Progenitor cells of mesodermal lineage
MY181994A (en) Immuno-modulatory progenitor (imp) cell
TW201611843A (en) Methods of treatment with arginine deiminase
MA40620A (en) VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
WO2014210037A3 (en) A composition of mesenchymal stem cells
MX2015014344A (en) Cancer therapy.
SG10201804034QA (en) Methods for treating hypotension
TR201902517T4 (en) Treatment of conditions associated with increased eotaxin with 25-hydroxyvitamin D3.
MX2020002852A (en) Improved treatment of atopic dermatitis with tradipitant.
MX2018000052A (en) Compositions and methods for combination therapy with dengue virus and dendritic cells.
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
TW201612313A (en) Uses of ligustilide
MX2023007706A (en) Nanoparticles for use as a therapeutic vaccine.